Discover
PHAT
Phathom Pharmaceuticals, Inc.
5.74
2 x 4.48
2 x 7.23
bid
ask
-
0.48
7.72%
2 @ 06:36 PM
5.85 +0.11 (1.92%)
| Ytd | -65.40% | |
| 1y | -56.87% |
5.59
day range
6.32
5.01
52 week range
18.31
| Open | 6.32 | Prev Close | 6.22 | Low | 5.59 | High | 6.32 | Mkt Cap | 466.61M |
| Vol | 1.62M | Avg Vol | 1.46M | EPS | -1.26 | P/E | N/A | Forward P/E | 7.60 |
| Beta | 0.61 | Short Ratio | 9.36 | Inst. Own | 83.10% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 7.70 | 200-d Avg | 10.49 | 1yr Est | 23.70 |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-03-27 | Barclays | Upgrade | Equal-Weight | Overweight |
| 2026-02-27 | Guggenheim | Upgrade | Buy | Buy |
| 2025-12-09 | Barclays | Upgrade | Equal-Weight | |
| 2025-10-31 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2025-06-09 | Craig-Hallum | Upgrade | Buy | Buy |
| 2025-06-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-09 | BASTA STEVEN L | Chief Executive Officer | 373.32K | Stock Award(Grant) |
| 2026-02-26 | BREEDLOVE ROBERT CHARLES | Officer | 68.43K | Stock Award(Grant) |
| 2026-02-09 | COOK ANNE MARIE | Officer | 88.66K | Stock Award(Grant) |
| 2025-01-20 | CURRAN TERRIE | President | 364.31K | Sale |
| 2025-04-06 | HENDERSON MOLLY | Chairman of the Board | 91.78K | Sale |
| 2025-02-26 | NABULSI AZMI M.D. | Chief Operating Officer | 1.10M | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | Frazier Life Sciences Management, L.P. | 12.47M | 146.23M | 15.69% |
| 2026-03-30 | Medicxi Ventures Management (Jersey) Ltd | 7.46M | 87.56M | 9.40% |
| 2025-12-30 | Invesco Ltd. | 3.92M | 45.99M | 4.94% |
| 2025-12-30 | Blackrock Inc. | 3.56M | 41.71M | 4.48% |
| 2025-12-30 | Carlyle Group Inc. | 3.50M | 41.02M | 4.40% |
| 2025-12-30 | Vanguard Group Inc | 3.18M | 37.27M | 4.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-01-30 | AIM Intl Mutual Fd.s -Invesco Global Fd. | 2.34M | 27.48M | 2.95% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.82M | 21.37M | 2.29% |
| 2026-02-27 | iShares Trust-iShares Russell 2000 ETF | 982.13K | 11.52M | 1.24% |
| 2026-02-27 | Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 968.55K | 11.36M | 1.22% |
| 2025-12-30 | WASATCH FUNDS TRUST-Wasatch Micro Cap Fund | 749.13K | 8.79M | 0.94% |
| 2025-12-30 | WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund | 563.44K | 6.61M | 0.71% |